Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report specifically addresses a notification of transactions involving directors and persons discharging managerial responsibility related to the company's US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share allocation event rather than general financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), the Plan Administrators notified the company and specific individuals of an increase in the notional allocation of Ordinary share ADRs on March 4, 2011. The transaction occurred at a price of $38.48 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the specific number of ADRs allocated to Dr. K. Belmonte (39), Mr. W. C. Louv (94), Dr. M. M. Slaoui (54), and Dr. D. Pulman (74).
- Confirm the transaction price of $38.48 per ADR on March 4, 2011.
- Note that this filing does not contain financial results for the period.